A number of other research firms have also recently commented on ICPT. Oppenheimer Holdings Inc. reissued a buy rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 1st. Goldman Sachs Group Inc. boosted their target price on shares of Intercept Pharmaceuticals from $114.00 to $128.00 and gave the stock a neutral rating in a research note on Tuesday, May 31st. Laidlaw cut shares of Intercept Pharmaceuticals from a buy rating to a sell rating and cut their target price for the stock from $345.00 to $105.00 in a research note on Friday, August 5th. Robert W. Baird reissued an outperform rating and set a $332.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 1st. Finally, Wedbush restated an outperform rating and set a $239.00 price target (down from $423.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 31st. Five equities research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $177.67.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 162.38 on Wednesday. Intercept Pharmaceuticals has a 12 month low of $89.76 and a 12 month high of $217.99. The stock’s 50 day moving average is $159.00 and its 200-day moving average is $150.17. The stock’s market capitalization is $4.02 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, topping analysts’ consensus estimates of ($3.69) by $0.55. The business earned $5.52 million during the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The company’s quarterly revenue was up 1140.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.99) earnings per share. On average, equities research analysts expect that Intercept Pharmaceuticals will post ($16.31) earnings per share for the current year.
In related news, insider Lisa Bright sold 246 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $159.00, for a total transaction of $39,114.00. Following the sale, the insider now directly owns 18,460 shares of the company’s stock, valued at approximately $2,935,140. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mark Pruzanski sold 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the sale, the chief executive officer now directly owns 579,314 shares in the company, valued at $95,586,810. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.
Large investors have recently made changes to their positions in the company. Aperio Group LLC increased its stake in shares of Intercept Pharmaceuticals by 31.2% in the first quarter. Aperio Group LLC now owns 2,152 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 512 shares in the last quarter. BlackRock Inc. increased its stake in shares of Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 1,438 shares in the last quarter. BlackRock Group LTD increased its stake in shares of Intercept Pharmaceuticals by 20.1% in the first quarter. BlackRock Group LTD now owns 13,074 shares of the biopharmaceutical company’s stock worth $1,680,000 after buying an additional 2,188 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock worth $60,030,000 after buying an additional 31,289 shares in the last quarter. Finally, Marcus Capital LLC purchased a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $1,317,000. 81.86% of the stock is currently owned by hedge funds and other institutional investors.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.